Business
Cogent Biosciences, Inc.: These risks include, but are not limited to, the following: Our business is highly dependent on the success of our bezuclastinib program and our ability to discover and develop additional product candidates.
Net income decreased 28.6% to ($328.9M), while Operating cash flow decreased 27.3% to ($264.4M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($328.9M)Watch
- Cash generation — Free cash flow ($266.0M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 0 buys; 6 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Latest filings
- 8-K · Company announcement2026-09-02
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-06-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cogent Biosciences, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.